



- Translation -

Ref : LPH/SET 2023/009

May 15, 2023

Subject : Clarification on the Operating Results for the 3-month period ended March 31, 2023 (Q1/2023)

To : President The Stock Exchange of Thailand

The Board of Directors' Meeting of Ladprao General Hospital Public Company Limited (the "Company"), No.2/2023, held on May 15, 2023, has approved the financial statements of the Company and its subsidiaries for the 3-month period ended March 31, 2023, and would like to clarify the operating results as follows:

Summary for Q1/2023 operating results

The Company and its subsidiaries recorded total consolidated revenues for Q1/2023 at Baht 499.20 million, a 30.14% YoY decrease which resulted in Baht 17.03 million of consolidated net profit (attributable to owners of the Company), 88.76% down from last year, mainly due to end of need for treatment under the pandemic while income from normal causes for general clients excluding social security has continuously grown. The structure of revenues, costs, and expenses comprised the followings:

Revenue

- Income from general clients- normal cause of business increased Baht 7.87 million at 3.05% YoY.
- Income from social security- normal cause of business decreased Baht 10.18 million at 6.65% YoY.
However, the Social Security Office has just approved an increase in the payment of medical services to contracted hospitals effectively from May 1, 2023, onwards.
- Revenue from health promotion business was lower than those generated in the first quarter of last year by Baht 47.85 million or 74.71%, mainly due to the fact that Covid-19 epidemic had motivated the income from COVID vaccination services and the revenue from health check-ups which had been postponed from the second half of 2021 to completion at the early of 2022 to be higher than usual business occurred in this quarter.
- Revenue from treating covid-19 patients materially reduced in the number of Baht 165.14 million or a decline of 96.64% YoY from the end of the COVID-19 pandemic.
- Service revenues of the subsidiary, Asia Medical & Agricultural Laboratory and Research Center PLC ("AMARC"), for Q1/2023 increased 0.8% YoY as a result of the revenue increase of 10.6% from calibration and 6.8% from testing services which mainly driven by large food manufacturers, major retail groups, as well as expansion of service scopes and accreditation. However, revenues from the inspection and



- Translation -

-2-

certification service were 78.6% less, primarily due to the delay and declining public project bids and grants compared with the previous year.

Management of Costs and Expenses

The Company and its subsidiaries recorded total consolidated costs and expenses for Q1/2023 at Baht 476.48 million a 11.04% YoY decrease of Baht 59.13 million mainly caused by:

- Cost of medical treatment decreased by Baht 71.53 million or decline 17.24% YoY. The cost of such services mainly turned down due to the end of need of treatment under COVID-19 outbreak.
- The cost of subsidiary's services (AMARC) increased by 9.35% mainly from investment to support growth in parts of personnel, scientific equipment, as well as an impact of price hikes on chemicals and consumables.
- Consolidated services and administrative expenses increased 10.67% YoY of Baht 8.96 million. This was mainly due to the increase in administrative and marketing expenses for international customers, involving personnel at both the management and operational levels.

Please be informed accordingly.

Yours sincerely,

(Dr. Ungoon Chantanavich)
Chief Executive Officer